• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Xcovery joins NCI Formulary to help expedite cancer clinical trials

Xcovery joins NCI Formulary to help expedite cancer clinical trials

January 18, 2017
CenterWatch Staff

Xcovery, a developer of targeted therapeutics for cancer, has announced its participation in the NCI Formulary, a public-private partnership between the National Cancer Institute (NCI), part of the NIH, and pharmaceutical and biotechnology companies to expedite the use of agents in clinical trials. The partnership, which launched last week with fifteen targeted agents from six pharmaceutical companies, will seek to alleviate the lengthy process to develop new therapies for patients, and respond to the call for greater collaboration within the industry made by Vice President Biden’s Cancer Moonshot Initiative.

“Collaboration among pharmaceutical companies with the NCI and the NIH will speed up the development of novel therapies and benefits for patients down the line,” said Lieming Ding, M.D., Chairman of Xcovery. “Xcovery has focused on developing drugs with reduced toxicity, which allows for combination therapies. We’re excited to join the NCI Formulary by providing our ALK inhibitor, ensartinib, to the broad research community for additional development opportunities, particularly in combination therapy programs.”

Research indicates that combination therapies, which include drugs with different mechanisms of action impacting cancer cells in multiple ways, provide an improved clinical benefit and can decrease the risk of relapse. The establishment of the NCI Formulary will enable the NCI to facilitate and streamline the arrangements for access to and use of pharmaceutical agents from multiple organizations, allowing for further research on various therapeutic opportunities. Following Xcovery’s approval, investigators will be able to obtain and test ensartinib in new preclinical or clinical studies, including combination studies with formulary agents from different companies.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing